Karim F. Lalji
Directeur Général chez Microbion Corp.
Profil
Karim F.
Lalji is currently the Chief Executive Officer & Director at Microbion Corp., as well as a Director at The Centre for Drug Research & Development and Accel-Rx.
Previously, he held positions as a Director of Business Strategy at Merck & Co., Inc., Director at MSI Methylation Sciences, Inc., Director of the Overseers Board at Beth Israel Deaconess Medical Center, Inc., and Vice President of New Products Planning at Sumitomo Pharma America, Inc. From 2006 to 2015, he served as the Chief Commercial Officer at Correvio Pharma Corp.
Mr. Lalji has a graduate degree from Harvard University and an undergraduate degree from Simon Fraser University.
Postes actifs de Karim F. Lalji
| Sociétés | Poste | Début |
|---|---|---|
Accel-Rx
 Accel-Rx Financial ConglomeratesFinance Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - |
Microbion Corp.
 Microbion Corp. Pharmaceuticals: MajorHealth Technology Microbion Corp. develops topical microbial therapeutic products. It safeguards human health by overcoming infections, antibiotic resistance, and microbial biofilms with safe, effective anti-infective products. The firm is developing MBN-101 as the first product in a new class for the treatment of antibiotic-resistant and difficult to treat infections. The company was founded by Brett H. Baker and is headquartered in Bozeman, MT. | Directeur Général | - |
The Centre for Drug Research & Development
 The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Karim F. Lalji
| Sociétés | Poste | Fin |
|---|---|---|
| CORREVIO PHARMA CORP. | Corporate Officer/Principal | 16/02/2015 |
Beth Israel Deaconess Medical Center, Inc.
 Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Directeur/Membre du Conseil | - |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | - |
Formation de Karim F. Lalji
| Harvard University | Graduate Degree |
| Simon Fraser University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Correvio Pharma Corp.
 Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Microbion Corp.
Microbion Corp. Pharmaceuticals: MajorHealth Technology Microbion Corp. develops topical microbial therapeutic products. It safeguards human health by overcoming infections, antibiotic resistance, and microbial biofilms with safe, effective anti-infective products. The firm is developing MBN-101 as the first product in a new class for the treatment of antibiotic-resistant and difficult to treat infections. The company was founded by Brett H. Baker and is headquartered in Bozeman, MT. | Health Technology |
MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Health Services |
The Centre for Drug Research & Development
The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada. | Commercial Services |
Accel-Rx
Accel-Rx Financial ConglomeratesFinance Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada. | Finance |
